Finerenone in Heart Failure With Improved Ejection Fraction

This prespecified analysis of a randomized trial examines profiles, risk, and response to finerenone among patients with hearth failure with improved ejection fraction compared with patients with left ventricular ejection faction consistently 40% or higher.